Guangdong-based Jianke Pharmaceutical, operator of B2C pharmaceutical e-tailer Jianke.com, has completed USD 50 mln in Series A+ funding, announced Jianke CEO Xie Fangmin. The funding came from investment firms Asia-Pac Ecommerce, Penta Global Advisors Fund, and Huashanshi Investment Management.
The funding will be used for investments in chronic disease management, internet medicine, and exploration of smart healthcare services.
Jianke is planning to launch a number of brick-and-mortar hospitals nationwide, which will serve as a key path towards developing an internet hospital business, revealed Xie. Jianke has completed preparation for an IPO in the United States, and is planning to list on the Nasdaq within the next 2-3 years, according to Xie. However, the company has not eliminated the possibility of listing on a different exchange.
Editor's Note: The company also operates mobile B2C e-commerce app Jianke Doctor (formerly called Palm Doctor), which lets users engage in online consultations with doctors, read health news, perform self-diagnosis based on online descriptions of medical symptoms, and buy drugs through an online pharmacy. Jianke.com also provides similar services to the mobile app. For more information on this topic, please see "B2C Pharmaceutical E-tailer 'Jianke' Lands USD 100 Mln Series A," MD 1/28/16 issue.